SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/89BAABA3E6B3DC235E82FB88C9660E0070D2E4E76E1BEA2C9536A4EB96B5144DC9DABA82456D0E78B9CEBDB301E9F45F>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/89BAABA3E6B3DC235E82FB88C9660E0070D2E4E76E1BEA2C9536A4EB96B5144DC9DABA82456D0E78B9CEBDB301E9F45F
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/89BAABA3E6B3DC235E82FB88C9660E0070D2E4E76E1BEA2C9536A4EB96B5144DC9DABA82456D0E78B9CEBDB301E9F45F
http://www.w3.org/2000/01/rdf-schema#comment
"These results suggest that the in vivo mechanism of non-ligand-blocking epratuzumab may in part involve the unmasking of CD22 to facilitate the trans-interaction of B cells with vascular endothelium."
xsd:string
http://purl.uniprot.org/uniprot/#_C5E4215CB60E401781768C2C7E7482C8AE1CC2125447E4FC1E8652A33B9A4F74BBBA8E024CDE824B85FBAB26E086BAAD
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/89BAABA3E6B3DC235E82FB88C9660E0070D2E4E76E1BEA2C9536A4EB96B5144DC9DABA82456D0E78B9CEBDB301E9F45F
http://purl.uniprot.org/uniprot/Q9UQB2
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/89BAABA3E6B3DC235E82FB88C9660E0070D2E4E76E1BEA2C9536A4EB96B5144DC9DABA82456D0E78B9CEBDB301E9F45F
http://purl.uniprot.org/uniprot/#_Q9UQB2-mappedCitation-25484043
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/89BAABA3E6B3DC235E82FB88C9660E0070D2E4E76E1BEA2C9536A4EB96B5144DC9DABA82456D0E78B9CEBDB301E9F45F